These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 12528774)

  • 1. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).
    Van den Abbeele AD; Badawi RD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S60-5. PubMed ID: 12528774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F-18 FDG PET imaging in gastrointestinal stromal tumor.
    Reddy MP; Reddy P; Lilien DL
    Clin Nucl Med; 2003 Aug; 28(8):677-9. PubMed ID: 12897659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [FDG-PET and CT in gastrointestinal stromal tumor treated with imatinib].
    Eigtved AI; Berthelsen AK; Kinnander C; Krarup-Hansen A
    Ugeskr Laeger; 2003 Sep; 165(37):3507-9. PubMed ID: 14531350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
    Stroobants S; Goeminne J; Seegers M; Dimitrijevic S; Dupont P; Nuyts J; Martens M; van den Borne B; Cole P; Sciot R; Dumez H; Silberman S; Mortelmans L; van Oosterom A
    Eur J Cancer; 2003 Sep; 39(14):2012-20. PubMed ID: 12957455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
    Jager PL; Gietema JA; van der Graaf WT
    Nucl Med Commun; 2004 May; 25(5):433-8. PubMed ID: 15100500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    Demetri GD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
    Valls-Ferrusola E; García-Garzón JR; Ponce-López A; Soler-Peter M; Fuertes-Cabero S; Moragas-Solanes M; Riera-Gil E; Carrió-Gasset I; Lomeña-Caballero F
    Rev Esp Enferm Dig; 2012 Jul; 104(7):360-6. PubMed ID: 22849497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
    Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
    Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts.
    Silberman S; Joensuu H
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S66-9. PubMed ID: 12528775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
    Van den Abbeele AD; Gatsonis C; de Vries DJ; Melenevsky Y; Szot-Barnes A; Yap JT; Godwin AK; Rink L; Huang M; Blevins M; Sicks J; Eisenberg B; Siegel BA
    J Nucl Med; 2012 Apr; 53(4):567-74. PubMed ID: 22381410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.
    Antoch G; Kanja J; Bauer S; Kuehl H; Renzing-Koehler K; Schuette J; Bockisch A; Debatin JF; Freudenberg LS
    J Nucl Med; 2004 Mar; 45(3):357-65. PubMed ID: 15001674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal stromal tumors: chemotherapy and imatinib.
    Muler JH; Baker L; Zalupski MM
    Curr Oncol Rep; 2002 Nov; 4(6):499-503. PubMed ID: 12354362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
    Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
    J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging.
    Zincirkeser S; Sevinc A; Kalender ME; Camci C
    World J Gastroenterol; 2007 Apr; 13(15):2261-2. PubMed ID: 17465516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review.
    Treglia G; Mirk P; Stefanelli A; Rufini V; Giordano A; Bonomo L
    Clin Imaging; 2012; 36(3):167-75. PubMed ID: 22542374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
    Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
    Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate.
    Abhyankar SA; Nair N
    Clin Nucl Med; 2008 Mar; 33(3):213-4. PubMed ID: 18287851
    [No Abstract]   [Full Text] [Related]  

  • 20. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.